Cartilage Repair Market Size, Share & Analysis Report, 2023-2032
The global cartilage repair market size was exhibited at USD 1.65 billion in 2022 and is projected to hit around USD 5.19 billion by 2032, growing at a CAGR of 12.14% during the forecast period 2023 to 2032.
Key Pointers:
Cartilage Repair Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 1.85 Billion |
|
Market Size by 2032 |
USD 5.19 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 12.14% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
By Type, By Application, By Treatment Type and By Site |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
Smith+ Nephew, Stryker, Zimmer Biomet, B. Braun Melsungen AG, The Future of Biotechnology, MEDIPOST, Vericel Corporation, CONMED Corporation, Medical Devices Business Services, Meril Life Sciences Pvt. Ltd., Arthrex, Inc., Medacta International, Teijin Nakashima Medical Co., Ltd., BioTissue SA, ISTO Technologies, Inc., CartiHeal, Inc., Mathys AG Bettlach, Waldemar Link GmbH & Co.KG, JRI Orthopaedics, Regentis Biomaterials Ltd. and Others. |
Cartilage Repair Market Dynamics
Drivers: Increasing incidence of osteoarthritis
Over the years, the incidence of osteoarthritis has increased across the globe. According to a study by the University of North Carolina, around 1 million knee and hip replacement procedures are conducted every year in the US. The economic burden of osteoarthritis in the US is ~139.8 billion annually. As per the Arthritis Foundation in 2022, degenerative joint diseases such as osteoarthritis will affect more than 131 million patients worldwide by 2050.
Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and Scaffolds implants Thus, the increasing incidence of osteoarthritis is expected to drive the demand for cartilage repair and regeneration products.
Restraints: High cost of cartilage repair surgeries
Although cartilage repair surgeries offer better and long-lasting results as compared to total knee replacement surgeries, the cost of these therapies is one of the major factors limiting their adoption among patients. The average cost for knee replacement procedures is around USD 16,000, while the average cost of cartilage repair procedures is around USD 18,000–USD 23,000, depending on the region where the procedure is being performed. Such high costs underrate the results of cartilage repair therapies, and in turn, result in a lower preference for these procedures as compared to knee replacement surgeries.
Opportunities: Technological advancements
As a result of the rising government investments in regenerative medicine for cartilage regeneration research, the number of companies focusing on the development of cartilage regeneration products has increased significantly over the last few years. As a result of these factors, the number of clinical trials and the development of new technologies for cartilage regeneration has increased. Major players in this market are making significant investments in R&D, resulting in a strong pipeline of products based on various approaches to cartilage repair.
Challenges: Limitation of cartilage-based stem cell products
Active research is ongoing to identify an exhaustive universal source of progenitor cells, such as embryonic stem cells and induced pluripotent stem cells, for cartilage repair and regeneration. However, there are major challenges associated with their clinical use due to ethical considerations and safety issues, such as immune rejection, tumorigenesis, and teratoma formation. In order to monitor these activities, strict regulations have been formulated by authorities such as the Human Tissue Authority (HTA), Human Fertilization and Embryology Authority (HFEA), Medicines and Healthcare Products Regulatory Agency (MHRA), and the Central Ethics Committee for Stem Cell Research. Due to the presence of these organizations, coupled with the ethical concerns on the use of embryonic stem cells in research and development activities, regenerative medicine research is being restricted to a great extent in various countries across the globe. Other issues related to the effective use of stem cells include reduced potentiality with age and disease and production of fibrocartilage instead of hyaline cartilage at the site of damage. With stringent regulations in place, a large number of products under development do not proceed to the marketing approval stage as they cannot clear the safety and efficacy requirements.
Some of the prominent players in the Cartilage Repair Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Cartilage Repair market.
By Type
By Application
By Treatment Type
By Site
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cartilage Repair Market
5.1. COVID-19 Landscape: Cartilage Repair Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cartilage Repair Market, By Type
8.1. Cartilage Repair Market, by Type, 2023-2032
8.1.1. Cell-Based
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Non-Cell-Based
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cartilage Repair Market, By Application
9.1. Cartilage Repair Market, by Application, 2023-2032
9.1.1. Hyaline
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Fibrocartilage
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cartilage Repair Market, By Treatment Type
10.1. Cartilage Repair Market, by Treatment Type, 2023-2032
10.1.1. Palliative
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Intrinsic Repair Stimulus
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Cartilage Repair Market, By Site
11.1. Cartilage Repair Market, by Site, 2023-2032
11.1.1. Knee Cartilage Repair
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Other
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Cartilage Repair Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.4. Market Revenue and Forecast, by Site (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Site (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.4. Market Revenue and Forecast, by Site (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Site (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Site (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Site (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.4. Market Revenue and Forecast, by Site (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Site (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Site (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Site (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.4. Market Revenue and Forecast, by Site (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Site (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Site (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Site (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Site (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Site (2020-2032)
Chapter 13. Company Profiles
13.1. Smith+ Nephew
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Stryker
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Zimmer Biomet
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. B. Braun Melsungen AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Future of Biotechnology
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. MEDIPOST
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Vericel Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. CONMED Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Medical Devices Business Services (DePuy Synthes)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Meril Life Sciences Pvt. Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers